BACKGROUND: Cancer-related fatigue (CRF) is associated with negative health outcomes and decreased health-related quality of life; however, few longitudinal studies have investigated molecular-genetic mechanisms of CRF. OBJECTIVE: The objective of this study was to describe relationships between mitochondria-related gene expression changes and self-reported fatigue in prostate cancer patients receiving external beam radiation therapy (EBRT). METHODS: A prospective, exploratory, and repeated-measures design was used. Self-report questionnaires and peripheral whole-blood samples were collected from 15 patients at 7 time points. Baseline data were compared against 15 healthy controls. The Human Mitochondria RT Profiler PCR Array was used to identify differential regulation of genes involved in mitochondrial biogenesis and function. RESULTS: Compared with baseline, there were significant increases in fatigue scores (P = .02-.04) and changes in mitochondria-related gene expression (P = .001-.05) over time. Mean fatigue scores were 1.66 (SD, 1.66) at baseline, 3.06 (SD, 1.95) at EBRT midpoint, 2.98 (SD, 2.20) at EBRT completion, and 2.64 (SD, 2.56) at 30 days after EBRT. Over time, 11 genes related to mitochondrial function and structure were differentially expressed. Of these 11 genes, 3 (BCL2L1, FIS1, SLC25A37) were more than 2.5 fold up-regulated, and 8 (AIFM2, BCL2, IMMP2L, MIPEP, MSTO1, NEFL, SLC25A23, SLC25A4) were greater than 2-fold down-regulated. Furthermore, 8 genes (AIFM2, BCL2, FIS1, IMMP2L, MSTO1, SLC25A23, SLC25A37, SLC25A4) were significantly associated with the changes in fatigue scores. CONCLUSION: This study provides preliminary evidence that 8 mitochondrial function genes were significantly associated with fatigue in prostate cancer patients during EBRT. IMPLICATIONS FOR PRACTICE: These findings identify possible pathways and early biomarkers for targeting novel interventions for CRF.
BACKGROUND:Cancer-related fatigue (CRF) is associated with negative health outcomes and decreased health-related quality of life; however, few longitudinal studies have investigated molecular-genetic mechanisms of CRF. OBJECTIVE: The objective of this study was to describe relationships between mitochondria-related gene expression changes and self-reported fatigue in prostate cancerpatients receiving external beam radiation therapy (EBRT). METHODS: A prospective, exploratory, and repeated-measures design was used. Self-report questionnaires and peripheral whole-blood samples were collected from 15 patients at 7 time points. Baseline data were compared against 15 healthy controls. The Human Mitochondria RT Profiler PCR Array was used to identify differential regulation of genes involved in mitochondrial biogenesis and function. RESULTS: Compared with baseline, there were significant increases in fatigue scores (P = .02-.04) and changes in mitochondria-related gene expression (P = .001-.05) over time. Mean fatigue scores were 1.66 (SD, 1.66) at baseline, 3.06 (SD, 1.95) at EBRT midpoint, 2.98 (SD, 2.20) at EBRT completion, and 2.64 (SD, 2.56) at 30 days after EBRT. Over time, 11 genes related to mitochondrial function and structure were differentially expressed. Of these 11 genes, 3 (BCL2L1, FIS1, SLC25A37) were more than 2.5 fold up-regulated, and 8 (AIFM2, BCL2, IMMP2L, MIPEP, MSTO1, NEFL, SLC25A23, SLC25A4) were greater than 2-fold down-regulated. Furthermore, 8 genes (AIFM2, BCL2, FIS1, IMMP2L, MSTO1, SLC25A23, SLC25A37, SLC25A4) were significantly associated with the changes in fatigue scores. CONCLUSION: This study provides preliminary evidence that 8 mitochondrial function genes were significantly associated with fatigue in prostate cancerpatients during EBRT. IMPLICATIONS FOR PRACTICE: These findings identify possible pathways and early biomarkers for targeting novel interventions for CRF.
Authors: Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: Christine Miaskowski; Steven M Paul; Bruce A Cooper; Kathryn Lee; Marylin Dodd; Claudia West; Bradley E Aouizerat; Patrick S Swift; William Wara Journal: J Pain Symptom Manage Date: 2008-03-20 Impact factor: 3.612
Authors: Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså Journal: Lancet Date: 2008-12-16 Impact factor: 79.321
Authors: Divya Lenkala; Bonnie LaCroix; Eric R Gamazon; Paul Geeleher; Hae Kyung Im; R Stephanie Huang Journal: Hum Genet Date: 2014-03-08 Impact factor: 4.132
Authors: Kathleen C Light; Neeraj Agarwal; Eli Iacob; Andrea T White; Anita Y Kinney; Timothy A VanHaitsma; Hannah Aizad; Ronald W Hughen; Lucinda Bateman; Alan R Light Journal: Psychoneuroendocrinology Date: 2013-09-06 Impact factor: 4.905
Authors: Velda J Gonzalez; Leorey N Saligan; Brooke L Fridley; Humberto Ortiz-Zuazaga; Lauren S Aaronson Journal: P R Health Sci J Date: 2017-12 Impact factor: 0.705
Authors: Kord M Kober; Laura Dunn; Judy Mastick; Bruce Cooper; Dale Langford; Michelle Melisko; Alan Venook; Lee-May Chen; Fay Wright; Marilyn Hammer; Brian L Schmidt; Jon Levine; Christine Miaskowski; Bradley E Aouizerat Journal: Biol Res Nurs Date: 2016-03-08 Impact factor: 2.522